

NEUROCRINE BIOSCIENCES INC
Form 8-K
July 25, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): July 24, 2003

NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

0-28150
(Commission File Number)

33-0525145
(IRS Employer Identification No.)

10555 Science Center Drive, San Diego, CA
(Address of principal executive offices)

92121
(Zip Code)

Registrant's telephone number, including area code: **(858) 658-7600**

N/A

(Former name or former address, if changed since last report.)

This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the Company), in connection with the matters described herein.

ITEM 5. OTHER EVENTS

On July 24, 2003, the Company announced the appointment of Wendell Wierenga to the position of Executive Vice President Research and Development. A press release related to this appointment is attached to this report as Exhibit 99.1 and incorporated herein by reference.

ITEM 7. EXHIBITS

(c) EXHIBITS. The following exhibits are filed herewith:

Exhibit

Number Description of Exhibit

99 Press Release dated July 24, 2003

ITEM 5. OTHER EVENTS

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: July 24, 2003

/s/ Paul W. Hawran

Paul W. Hawran
Executive Vice President
and Chief Financial Officer

2
